Multiple Myeloma Management: Promising Advances in Treating Heavily Pretreated Patients
"Explore innovative approaches in treating relapsed and refractory multiple myeloma, including the use of Pomalidomide-Dexamethasone and optimized infection management strategies."
Multiple myeloma (MM) remains a challenging hematological malignancy, particularly when patients become resistant to standard treatments. Recent research has focused on improving outcomes for these heavily pretreated individuals, exploring new therapeutic combinations and strategies to manage treatment-related complications.
This article synthesizes findings from several studies presented at a recent hematology conference, highlighting the use of pomalidomide-dexamethasone in relapsed and refractory MM (rrMM), infection risk management during monoclonal antibody therapy, and innovative approaches to treating hyperviscosity syndrome associated with plasma cell dyscrasias. Each of these areas represents a significant step forward in enhancing the quality of life and survival rates for MM patients.
By examining these targeted interventions, we aim to provide patients, caregivers, and healthcare professionals with an accessible overview of the latest advancements in MM care, offering hope and practical insights for managing this complex disease.
Pomalidomide in Relapsed or Refractory Myeloma
A 2023 meta-analysis assessed pomalidomide-based combination regimens for relapsed or refractory multiple myeloma (RRMM) in patients previously treated with lenalidomide. It pooled efficacy outcomes including overall response rate, complete response rate, and progression-free survival across multiple trials. The available source material does not provide the pooled figures, so those outcomes cannot be quantified here. The National Cancer Institute described pomalidomide plus low-dose dexamethasone as an important addition to treatment for advanced refractory or relapsed and refractory myeloma.
From Early Descriptions to Pomalidomide
A historical review traces multiple myeloma from the first case description in 1844 and discusses advances in understanding the disease and its treatment. Milestones highlighted include the definition of Bence Jones proteinuria, characterization of tumoral plasma cells and serum globulins, and Jan Waldenstrom’s contribution. The review reports that melphalan and prednisone treatment began in the late 1960s and achieved median overall survival of 3–4 years. A later treatment milestone was FDA approval of pomalidomide, based on a phase II randomized study of patients refractory to their last therapy who had previously received lenalidomide and bortezomib.
Pomalidomide-Dexamethasone: A New Hope for Heavily Pretreated MM
Pomalidomide, a new-generation IMID (immunomodulatory drug), has shown promise in treating heavily pretreated multiple myeloma due to its oral administration and good compliance. A retrospective study evaluated the efficacy and tolerance of pomalidomide plus dexamethasone (PD) as a salvage regimen in patients with relapsed and refractory MM (rrMM), a population with particularly poor prognoses.
- Grade 3 anemia was observed in 48% of patients (14/29).
- Grade 3 neutropenia occurred in 31% (9/29) of patients, managed with pegfilgrastim prophylaxis to avoid hospitalization and septic shocks.
- Grade 3-4 thrombocytopenia without hemorrhagic events and transfusion-dependence was noted in 27% (8/29) of patients.
Talquetamab Combinations and Pomalidomide Studies
The MonumenTAL-3 findings summarized by Nature Reviews Clinical Oncology report that talquetamab, a GPRC5D-directed bispecific T-cell engager, combined with either daratumumab or daratumumab–pomalidomide produced significantly longer progression-free survival than daratumumab–pomalidomide–dexamethasone. The comparison involved patients with relapsed or refractory multiple myeloma who had received at least one prior line of therapy. Separately, the phase 2 MM-014 trial reported updated efficacy, safety, and health-related quality-of-life results for pomalidomide, dexamethasone, and daratumumab given immediately after lenalidomide-based treatment. The supplied snippet does not include the MM-014 results.
Real-World Evidence and Remaining Questions
A retrospective real-world analysis examined the tolerability and safety of pomalidomide in 14 patients with relapsed or refractory multiple myeloma previously refractory to lenalidomide and bortezomib. Another report describes pomalidomide–dexamethasone as standard care for relapsed and refractory disease since 2013, while noting that outcomes after exposure to CD38 antibodies were not known. A separate retrospective study focused on the use, tolerance, and outcomes of generic pomalidomide in RRMM refractory to bortezomib and lenalidomide. Its source snippet describes the prognosis as poor, with median survival between 3 and 9 months.
Optimizing Infection Management in the Era of Monoclonal Antibody Therapy
The introduction of monoclonal antibody therapies like elotuzumab and daratumumab has transformed the treatment landscape for multiple myeloma. However, these therapies can also increase the risk of infections. A retrospective study aimed to identify the incidence and types of infections in MM patients receiving these monoclonal antibodies to better inform infection prophylaxis strategies. The study included 51 patients treated with elotuzumab, daratumumab, or both. All patients received anti-viral prophylaxis.
A Broader and Still Evolving Treatment Horizon
A 2026 analysis set out to evaluate multiple myeloma drug candidates in clinical trials from 2014 to 2024. Its background describes emerging therapies as having improved outcomes and advanced treatment toward more targeted, effective, and less toxic approaches, while emphasizing that the disease remains incurable. A separate 2022 review discusses gaps in translating targeted-therapy and immunotherapy advances into treatment and considers the potential of emerging preclinical research. A 2026 article frames quadruplets, CAR-T, and bispecifics as having transformed the treatment landscape and discusses what a possible cure might look like.